
The GEFCO Group, a provider of multimodal supply chain solutions and a European leader in automotive logistics, has received Good Distribution Practice (GDP) certification for the road transport of pharmaceutical products in nine additional countries, including Poland.
The certificate was granted by the independent and accredited body Bureau Veritas. GEFCO currently holds GDP certification for transport in 15 countries, which confirms the company’s commitment to developing quality management processes in the realities of a demanding market. The GEFCO Group has obtained GDP certification for road transport in: Poland, Bulgaria, Morocco, Serbia, Slovenia, Switzerland, Turkey, Italy, and the United Kingdom. In 2018, GEFCO underwent GDP certification in: the Czech Republic, Greece, Romania, Slovakia, Hungary, and France.
The Good Distribution Practice (GDP) certificate is valid for 3 years. It confirms that GEFCO meets the European Commission’s requirements set out in the guidelines on good distribution practice of medicinal products for human use. The awarding of the certificate to GEFCO highlights the company’s commitment to further improving quality and understanding the challenges faced by its customers regarding the tracking of goods flow and the prevention of counterfeit products.
– We are very pleased to have obtained the certificate for another nine countries in our network – says Tony Gunn, Executive Vice President of GEFCO Air & Sea. – Customers expect strict control and the highest safety standards, and we stand out for our quality in these areas. Thanks to GDP certification in further markets, we are stronger in terms of quality, which allows us to stand out from the competition and focus more on meeting the expectations of customers in this growing sector. We will continue to respond to the challenges faced by customers in the public and private sectors and strive to obtain certifications for road transport in further European countries in 2020.
The logistics market for the healthcare and life science sector is becoming increasingly complex. With the growing demand for home-use medicines, the volume of temperature-sensitive products being transported is increasing, which affects the need to maintain the integrity of the cold chain for pharmaceutical products. A Grand View Research report from April 2019 stated that the global logistics market for the pharmaceutical industry was valued at USD 76.4 billion in 2018 and will grow at a rate of 3.5% annually between 2019 and 2025. At the same time, regulations related to the transport of such products are becoming increasingly stringent. Supply chains are subject to strict regulations and require the organization of transport that meets the requirements defined by Good Distribution Practices, including, among others, detailed transit time limits or transport in strictly controlled temperatures. Logistics operators must support this industry by ensuring legal, safe, and timely transport. With extensive experience in logistics for the healthcare and life science sector, the GEFCO Group, through its global network, offers integrated door-to-door logistics services under temperature-controlled conditions. This is an important element in the implementation of the GEFCO Group’s strategy and meeting customer needs in line with the “Partners, unlimited” motto.
Source: GEFCO








